Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Avacta Group (AVCT) Share News

IN BRIEF: Avacta shareholders give AGM go-ahead to issue new shares

18th Mar 2024 14:31

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - At annual general meeting on Monday, shareholders approved the resolution to issue 23.9 million placing shares and 10.9 million Rex offer share, both at 50 pence each. This raises gross proceeds of around GBP11.9 million and GBP5.4 million respectively. Combined with proceeds from an earlier firm placing and direct subscription, the shares for which were admitted to trading on March 4, Avacta has raised total gross proceeds of GBP31.1 million. Read More

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

5th Mar 2024 17:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

Avacta increases placing size to GBP26 million thanks to strong demand

29th Feb 2024 12:18

(Alliance News) - Avacta Group PLC on Thursday said it is increasing its placing to GBP25.7 million, "in light of the strong demand." Read More

AIM WINNERS & LOSERS: Beacon Energy and Avacta fall on fundraise

29th Feb 2024 10:27

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday. Read More

TRADING UPDATES: Avacta plans fundraise to fund clinical development

28th Feb 2024 20:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

IN BRIEF: Avacta says new head of R&D Coughlin brings "deep expertise"

19th Jan 2024 09:11

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Appoints Christina Coughlin as head of research and development. Coughlin, who will take up the position on February 1, has served as a non-executive director of Avacta since March 2022 and was appointed consultant in interim in September 2023. She previously served as chief executive officer of Cytoimmune Therapeutics LLC, a clinical stage biotechnology company focused on novel cancer immunotherapy products. In the new role, Coughlin will oversee clinical and pre-clinical research and development activities for the company's therapeutics division, while retaining her position on as an executive director of Avacta. The company says that Coughlin has been "pivotal" in the development strategy for its AVA6000 tumour-targeted therapy. Read More

IN BRIEF: Avacta taps biopharma veteran as Therapeutics business chief

19th Dec 2023 09:57

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Hires Simon Bennett as chief business officer of Therapeutics division. Says Bennett has over 26 years of commercial experience in the biopharma industry and has "worked with" various large and mid-sized companies like Bristol-Myers Squibb Co and Menarini Group. Read More

Avacta says study shows cancer treatment AVA6000 working as planned

13th Dec 2023 11:49

(Alliance News) - Avacta Group PLC on Wednesday celebrated strong results from its latest cancer-targeting study, which showed the release of a chemotherapy to the tumour as intended. Read More

IN BRIEF: Avacta loss widens on cost rise but clinical tests positive

28th Sep 2023 11:08

Avacta Group PLC - Wetherby, England-based life sciences company that develops targeted oncology drugs and diagnostics - Pretax loss widens to GBP12.8 million in the six months that ended June 30 from GBP9.7 million a year before. Revenue doubles to GBP11.9 million from GBP5.5 million, but selling, general and administrative expenses near double as well, to GBP8.6 million from GBP4.7 million. Research costs are steady at GBP6.0 million. Has GBP26.0 million cash, up from GBP17.0 million a year before, though down from GBP41.8 million on December 31. Highlights success of AVA6000, a chemotherapy drug for cancer patients, in a Phase 1a clinical study. Avacta aims to complete a dose escalation safety study and provide results during the fourth quarter. Read More

UK earnings, trading statements calendar - next 7 days

21st Sep 2023 15:48

TRADING UPDATES: Capital inks contract; Lansdowne becomes cash shell

20th Sep 2023 14:37

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

Avacta notes "excellent" safety profile for prospective sarcoma drug

19th Sep 2023 13:36

(Alliance News) - Avacta Group PLC on Tuesday said it successfully completed the sixth dose escalation of the ALS-6000-101 phase 1 clinical trial, in which its AVA6000 soft tissue sarcoma treatment demonstrated an "excellent" safety profile. Read More

IN BRIEF: Avacta Group issues 3.8 million shares to make repayment

21st Jul 2023 16:00

Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Issues 3.8 million new shares of 10 pence each to settle quarterly principal of GBP2.6 million and interest repayment of GBP760,000. After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by GBP2.6 million to GBP44.2 million. Read More

UK shareholder meetings calendar - next 7 days

21st Jun 2023 15:43

Avacta says AVA6000 fifth dose escalation results "very favourable"

21st Jun 2023 09:58

(Alliance News) - Avacta Group PLC on Wednesday said it has completed the fifth dose escalation cohort in its phase 1 clinical study of AVA6000. Read More

IN BRIEF: Avacta says no fundraising imminent after market speculation

19th Jun 2023 12:43

Avacta Group PLC - Wetherby, England-based life sciences company developing targeted oncology drugs and diagnostics - Reponds to recent market speculation regarding a possible fundraising. Says no fundraising is imminent. Notes it has a strong cash balance of GBP27 million as at May 31 and expects strong new flow in the company months. Read More

LONDON MARKET OPEN: Stocks falter amid weaker outlook for China

19th Jun 2023 09:09

(Alliance News) - Stock prices in London opened lower on Monday, ahead of more interest rate decisions, and amid fears for China's slowing economic recovery. Read More

LONDON BRIEFING: Severn Trent deal sized up by CMA; Coca-Cola HBC buys

19th Jun 2023 07:53

(Alliance News) - Stocks in London are called lower on Monday, ahead of more central bank decisions, while a meeting between US Secretary of State Antony Blinken and his Chinese counterpart put relations between the two nations back under the spotlight. Read More

Avacta sees shares rise on new equity payment for South Korea venture

5th Jun 2023 12:06

(Alliance News) - Avacta Group PLC on Monday celebrated "rapid" progress on its joint venture in South Korea, following a second equity payment. Read More

Avacta enhances rapid test portfolio with GBP7.4 million Coris buy

1st Jun 2023 10:24

(Alliance News) - Avacta Group PLC on Thursday said that it has bought Coris Bioconcept SRL, adding a range of professional-use rapid tests to its product portfolio. Read More

FTSE 100 Latest

Value8,809.74

Change53.53